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Opinion statement
The risk of deep vein thrombosis (DVT) after stroke is increased in patients with
restricted mobility, a previous history of DVT, dehydration, or comorbidities such
as malignant diseases or clotting disorders. Patients with an increased risk of DVT
should receive prophylactic treatment. To reduce the chance of DVT, patients
should be mobilized as soon as possible and should be kept well hydrated.
Anti-embolism stockings cannot be recommended, because they have been demon-
strated not useful for preventing DVT or pulmonary embolism in patients with
stroke, and they are associated with a significantly increased risk of skin breaks.
The usefulness of intermittent pneumatic compression is currently under study in
a randomized clinical trial. Treatment with subcutaneously administered low-dose
unfractionated heparin is preferred to unfractionated heparin and may be consid-
ered in patients with ischemic stroke if the risk of DVT is estimated to be higher
than the risk of hemorrhagic complications. Aspirin may also be effective for
patients with ischemic stroke who have contraindications to anticoagulants, al-
though direct comparisons with anticoagulants are not available. In patients with
intracerebral hemorrhage, low-dose subcutaneous low-molecular-weight heparin is
probably safe after documentation of cessation of active bleeding, and may be
considered on an individual basis after 3 to 4 days from stroke onset.
Introduction
Patients with stroke have a relatively high risk of
deep vein thrombosis (DVT) because of immobility
and increased prothrombotic activity [1]. DVT in
the paralyzed leg of a stroke patient was described
as early as 1810 by Ferriar [1]. The clinical diagno-
sis of DVT may be difficult, as there are no reliable
clinical signs or symptoms that can be used for a
definite diagnosis. Most cases of DVT detected with
ancillary investigations is asymptomatic. The pre-
ferred method to diagnose DVT is currently Dopp-
ler ultrasonography, but 125I fibrinogen scanning,
venography, and MRI of the thrombus can also
be used. In patients with an ischemic stroke and a
severe handicap, assessment of d-dimer on day 9
after stroke has been associated with an increased
incidence of DVT [2]. Depending on the diagnostic
methods, DVT has been said to occur in up to 80%
of patients with ischemic stroke who did not re-
ceive prophylactic therapy [3]. Clinically relevant
DVT has been reported in 1% to 5% of the patients
[4]. DVT develops most often between days 2 and
7 after stroke onset; about 80% of all DVTs occur
within the first 10 days [5••]. The incidence of clin-
ically apparent DVT was studied in a large cohort
of hospitalized patients with stroke from 1979 to
2003 [1 ] . DVT was r epo r t ed in 0 .74% of
1,4109,000 patients with ischemic stroke and in
1.37% of 1,606,000 patients with hemorrhagic
stroke [1]. These rates did not change over the
25-year period of observation. The difference be-
tween patients with ischemic and hemorrhagic
stroke probably is the result of less rigid preventive
management and of a generally more severe focal
deficit in the second group. In the CLOTS-2 (Clots
in Legs Or sTockings after Stroke), DVT also oc-
curred about twice as often after hemorrhagic
stroke than after ischemic stroke [6••].
DVT is associated with increased mortality and
morbidity. In the International Stroke Trial (IST),
0.8% of patients who did not receive thrombosis
prophylaxis developed a clinically apparent pulmo-
nary embolism (PE) within the first 2 weeks after
stroke onset [7]. PE accounts for 13% to 25% of
early deaths after stroke [8]. Proximal thrombosis
is considered to carry a higher risk for PE than
thrombosis in the calves. The risk of DVT and PE
for patients with an acute ischemic stroke resembles
that of patients undergoing major surgical proce-
dures. The combination of DVT and PE occurred
in 1.17% of patients hospitalized with ischemic
stroke and in 1.93% of patients with hemorrhagic
stroke [1]. DVT also can lead to post-phlebitic leg
and varicose ulcers, and it can delay rehabilitation.
There is no evidence-based method of predict-
ing the occurrence of DVT after stroke. In the
CLOTS-2 trial, the following items were associated
with an increased risk of DVT: dependency before
stroke (OR, 3.06; 95% CI, 1.70–5.51), inability to
lift arms off bed (OR, 2.97; 95% CI, 1.68–5.26),
inability to lift both legs (OR, 2.09; 95% CI,
1.93–3.40), and history of DVT or PE (OR, 2.92;
95% CI, 1.42–5.97). Non-stroke-related factors that
increase the risk of DVT include increased age, obe-
sity, hormone therapy, a prothrombotic state, and





& Preliminary results suggest that early mobilization after stroke is not
harmful [9]. The usefulness of early mobilization after acute ischemic
stroke is currently tested in the multicenter A Very Early Rehabilita-
tion Trial (AVERT).
& Although the results of AVERT must be awaited for a definite
statement, early mobilization of patients with ischemic stroke can
be recommended, because it probably lessens the likelihood not
only of DVT and PE but also of pneumonia and pressure sores
[10, Class IV].
Hydration
& Dehydration after ischemic stroke is independently associated with
DVT [11]. In the context of DVT prophylaxis, fluid intake has not
been evaluated in a clinical trial, but current guidelines advocate
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specific attention to keep patients well hydrated in the early stage of
ischemic stroke [12, Class IV].
Graduated compression stockings
& A meta-analysis of 2,615 patients demonstrated that the use of
graduated compression stockings was not associated with a reduction
in risk of DVT (OR, 0.88; 95% CI, 0.72–1.08) or death (OR, 1.13;
95% CI, 0.87–1.47) [13]. This meta-analysis included the results of
the CLOTS-1 trial, which randomized 2,518 immobile patients with
acute stroke to thigh-length graduated compression stockings or no
stockings [5••]. The results of the CLOTS-2 trial, which randomized
3,114 patients to thigh-length or below-knee stockings, were pub-
lished after this meta-analysis [6••]. The CLOTS-1 trial showed that
that full-length stockings did not significantly reduce the risk of DVT,
as compared with no stockings; the absolute risk reduction was 0.5%
(95% CI, −1.9 to 2.9) [5••]. In the CLOTS-2 trial, there was a trend
towards increased DVT in the group that used knee-length stockings
as compared with thigh-length stockings; the absolute risk increase
was 2.5% (95% CI, 0.7–4.4) [6••]. Both types of stockings were as-
sociated with an increase in the risk of skin complications.
& The routine use of stockings cannot be recommended on the basis of
current evidence [6••, 13, Class I].
Intermittent pneumatic compression
& A meta-analysis of two trials with a total of 177 patients showed that
the use of intermittent pneumatic compression within the first week
after stroke onset was associated with a nonsignificant trend towards
a lower risk of DVT (OR, 0.45; 95%CI, 0.19–1.10), with no evidence of
an effect on deaths (OR, 1.04; 95% CI, 0.37–2.89) [13]. One of the
studies in this meta-analysis has addressed the benefits of intermittent
pneumatic compression in preventing DVT in 155 patients with intra-
cerebral hemorrhage [14]. The combination of elastic stockings and
intermittent pneumatic compression significantly decreased the occur-
rence of asymptomatic DVT, as compared with the use of elastic
stockings alone (relative risk, 0.29; 95% CI, 0.08–1.00) [14].
& Another meta-analysis showed that in high-risk patients the combi-
nation of antithrombotic treatment and intermittent pneumatic
compression significantly reduced the incidence of DVT as compared
with intermittent pneumatic compression alone; the risk dropped
from about 4% to 1% (OR, 0.43; 95% CI, 0.24–0.76) [15]. Com-
pared with pharmacologic prophylaxis alone, the use of combined
modalities also significantly reduced the incidence of DVT from
4.21% to 0.65% (OR, 0.16; 95% CI, 0.07–0.34) [15].
& Currently, in the multicenter randomized CLOTS-3 trial, the useful-
ness of intermittent pneumatic compression is being tested versus
routine care including aspirin, hydration, and the possible use of
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stockings. Pending the results of this trial, intermittent pneumatic
compression for the prevention of DVT in patients with an acute
stroke can only be recommended in the context of a clinical trial [13,
Class I].
Antithrombotic treatment in patients with ischemic stroke
Unfractionated heparin
& In a Cochrane meta-analysis, the use of subcutaneous and intrave-
nous unfractionated heparin, low-molecular-weight heparins, sub-
cutaneous and intravenous heparinoids, oral vitamin K antagonists,
and specific thrombin inhibitors was associated with a highly sig-
nificant reduction in the risk of DVT in patients with ischemic stroke
(OR, 0.21; 95% CI, 0.15–0.29), although the majority of DVTs
detected were subclinical and asymptomatic [16]. However, the In-
ternational Stroke Trial showed that the prevention of recurrent is-
chemic stroke by subcutaneous administration of unfractionated
heparin (5000 U or 12,500 U twice daily) was offset by a propor-
tional increase in the rate of intracranial hemorrhagic events, result-
ing in the absence of a net benefit from this preventive treatment [7].
Therefore, routine use of unfractionated heparin cannot be recom-
mended to prevent DVT [7, Class I].
Low-molecular-weight heparin
& A meta-analysis showed that low-molecular-weight heparin or hep-
arinoid reduces the risk of DVT (OR, 0.27; 95% CI, 0.08–0.96) in
patients with acute ischemic stroke as compared with placebo, but
they are associated with a twofold increase in the risk of extracranial
bleeding (OR, 2.17; 95% CI, 1.10–4.28) [17].
& Another meta-analysis showed that in patients with ischemic stroke,
prophylaxis with low-molecular-weight heparin or heparinoid was
associated with a significant reduction in the occurrence of DVT as
compared with standard unfractionated heparin (OR, 0.55; 95% CI,
0.44–0.70) [18].
& The open-label, randomized PREVAIL study compared 10 days’
treatment with prophylactic enoxaparin (40 mg once daily) with
unfractionated heparin (5000 U twice daily) for the prevention of the
combined end point of symptomatic or asymptomatic DVT or
symptomatic PE after acute ischemic stroke [19•]. Enoxaparin re-
duced the risk of DVT or PE; the absolute risk reduction was 7.9%
(95% CI, 4.2–11.6) [19•]. The composite of symptomatic intracra-
nial and major extracranial hemorrhage occurred in 1% of both
groups. It remains uncertain whether enoxaparin is also associated
with a clinical benefit. When considering the total cost of events and
drugs, enoxaparin was associated with cost-savings of $895 per pa-
tient compared with unfractionated heparin ($2,018 vs $2,913) [20].
& Despite a small but definite risk of major hemorrhage, low-molec-
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ular-weight heparin is the preferred medication for the prevention of
DVT in patients with ischemic stroke [18, 19•, Class I].
Antiplatelet therapy
& Information about antiplatelet therapy for the prevention of DVT is
scarce. A Cochrane review of two small trials including 133 patients
(fewer than 0.3% of the participants included in the overall review)
showed that antiplatelet therapy did not reduce the risk of DVT (OR,
0.78; 95% CI, 0.36–1.67) [21]. However, aspirin in the acute stage of
ischemic stroke is associated with a reduction in recurrent stroke and is
not associated with an excess of intracerebral hemorrhages [7]. There-
fore, it seems reasonable to conclude that routine use of aspirin alone in
patients with acute ischemic stroke is safe. It remains unclear whether
aspirin alone is as good as low-molecular-weight heparin for the pre-
vention of DVT.
& Aspirin alone may be an adequate antithrombotic agent to be used
for routine DVT prophylaxis in patients with acute ischemic stroke,
but this has not been demonstrated in a clinical trial [21, Class IV].
Antithrombotic treatment in patients with hemorrhagic stroke
& The role of anticoagulants in preventing DVT or PE following
acute hemorrhagic stroke is uncertain. A meta-analysis of four
studies (two randomized) involving 1,000 patients with acute
hemorrhagic stroke showed that the use of unfractionated hepa-
rin, heparinoid, or low-molecular-weight heparin was associated
with a nonsignificant reduction in the risk of DVT, from 4.2% to
3.3% (RR, 0.77; 95% CI, 0.44–1.34) [22]. The reduction in
mortality (16.1% vs 20.9%) also was not significant (RR, 0.76;
95% CI, 0.57–1.03), and anticoagulants were associated with a
nonsignificant increase in any hematoma enlargement (8.0% vs
4.0%; RR, 1.42; 95% CI, 0.57–3.53) [22].
& There are no clinical data on the usefulness of antiplatelet therapy for
the prevention of DVT in patients with hemorrhagic stroke, and this
type of therapy should be discouraged.
& After documentation of cessation of bleeding, low-dose subcutane-
ous low-molecular-weight heparin is probably safe in patients with
intracerebral hemorrhage. It may be considered on an individual
basis for patients with hemiplegia after 3 to 4 days from stroke onset
[22, 23, Class IV].
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